A study of navitoclax and ruxolitinib for myelofibrosis

This study is looking at navitoclax on its own or together with ruxolitinib for people who have myelofibrosis.

Myelofibrosis is a rare blood disorder. It causes scarring of the bone marrow so it can’t make blood cells properly.

Myelofibrosis can develop without having had any other medical condition. This is called primary myelofibrosis. It can also develop in people who have previous blood and bone marrow conditions such as polycythaemia vera or thrombocythaemia. This is called secondary myelofibrosis. This study is for people with either primary or secondary myelofibrosis.